87 related articles for article (PubMed ID: 32415836)
1. Response to "COVID-19 and ACEI/ARB: Not Associated?".
Schiffrin EL; Flack JM; Ito S; Muntner P; Webb RC
Am J Hypertens; 2020 Aug; 33(8):789-790. PubMed ID: 32415836
[No Abstract] [Full Text] [Related]
2. COVID-19 and ACEI/ARB: Not Associated?
Hajra A; Bandyopadhyay D
Am J Hypertens; 2020 Aug; 33(8):788. PubMed ID: 32415832
[No Abstract] [Full Text] [Related]
3. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Guo J; Huang Z; Lin L; Lv J
J Am Heart Assoc; 2020 Apr; 9(7):e016219. PubMed ID: 32233755
[No Abstract] [Full Text] [Related]
4. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension.
Yuan Y; Liu D; Zeng S; Wang S; Xu S; Wang Y; Yu R; Gao Y; Li H; Feng X; Zhou N; Zhao C; Gao Q
J Infect; 2020 Nov; 81(5):816-846. PubMed ID: 32800800
[No Abstract] [Full Text] [Related]
5. [Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
Huang W; Li T; Ling Y; Qian ZP; Zhang YY; Huang D; Xu SB; Liu XH; Xia L; Yang Y; Lu SH; Lu HZ
Zhonghua Nei Ke Za Zhi; 2020 Sep; 59(9):689-694. PubMed ID: 32838499
[No Abstract] [Full Text] [Related]
6. COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.
Kussmaul WG
Ann Intern Med; 2020 Aug; 173(3):237-238. PubMed ID: 32422077
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19.
Bae DJ; Tehrani DM; Rabadia SV; Frost M; Parikh RV; Calfon-Press M; Aksoy O; Umar S; Ardehali R; Rabbani A; Bokhoor P; Nsair A; Currier J; Tobis J; Fonarow GC; Dave R; Rafique AM
Am J Cardiol; 2020 Oct; 132():150-157. PubMed ID: 32819683
[TBL] [Abstract][Full Text] [Related]
8. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis.
Zhang X; Yu J; Pan LY; Jiang HY
Pharmacol Res; 2020 Aug; 158():104927. PubMed ID: 32422341
[TBL] [Abstract][Full Text] [Related]
9. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Baral R; White M; Vassiliou VS
Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
[TBL] [Abstract][Full Text] [Related]
10. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
[No Abstract] [Full Text] [Related]
11. Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Kansagara D; Mackey K; Vela K
Ann Intern Med; 2020 Aug; 173(3):W66. PubMed ID: 32584593
[No Abstract] [Full Text] [Related]
12. Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19.
Tan ND; Qiu Y; Xing XB; Ghosh S; Chen MH; Mao R
Gastroenterology; 2020 Sep; 159(3):1170-1172.e1. PubMed ID: 32422208
[No Abstract] [Full Text] [Related]
13. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
Diaz JH
J Travel Med; 2020 May; 27(3):. PubMed ID: 32186711
[TBL] [Abstract][Full Text] [Related]
14. Reply: ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.
Amat-Santos IJ; Santos-Martinez S; López-Otero D; Delgado-Arana JR; San Román JA
J Am Coll Cardiol; 2020 Oct; 76(17):2042. PubMed ID: 33092743
[No Abstract] [Full Text] [Related]
15. Commentary on "angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic".
Ferrario CM
Diabetes Metab Syndr; 2020; 14(5):1401-1402. PubMed ID: 32755842
[No Abstract] [Full Text] [Related]
16. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).
Thomas LE; Bonow RO; Pencina MJ
JAMA Cardiol; 2020 Sep; 5(9):988-990. PubMed ID: 32936260
[No Abstract] [Full Text] [Related]
17. Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
Gersh FL
Mayo Clin Proc; 2020 Jul; 95(7):1552-1553. PubMed ID: 32622456
[No Abstract] [Full Text] [Related]
18. ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.
Wang Y; Tse G; Li G; Lip GYH; Liu T
J Am Coll Cardiol; 2020 Oct; 76(17):2041. PubMed ID: 33092742
[No Abstract] [Full Text] [Related]
19. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.
Verdecchia P; Angeli F; Reboldi G
J Hypertens; 2020 Jun; 38(6):1190-1191. PubMed ID: 32371811
[No Abstract] [Full Text] [Related]
20. Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score.
Vavougios GD
Crit Care; 2020 May; 24(1):242. PubMed ID: 32430049
[No Abstract] [Full Text] [Related]
[Next] [New Search]